Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ZEVRA THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
12.8
13.3
28.7
10.2
27.5
23.6
106
Cost of revenue
0
10
2.06
0.22
2.95
7.42
16.5
Gross profit
0
2.84
26.6
9.94
24.5
16.2
90
Research and development
20.5
20.6
41.8
19.4
8.84
10.2
19.8
39.8
42.1
12.7
Selling, general and administrative
15
34.3
54.9
77.6
General and administrative
14
12.8
12.5
10.8
7.92
8.7
15.3
Operating expenses
37.5
33.4
55.9
Operating income
-37.5
-33.4
-55.9
-20.3
-5.61
7.73
-42.6
-49.6
-87
-62.9
Interest expense
5.51
5.78
5.47
4.86
4.79
0.23
0.34
1.5
7.35
7.98
Other non-operating income
21
-10.1
-0.69
-4.21
-7.19
-16.3
15.8
3.56
-3.14
150
Pre-tax income
-16.5
-43.4
-56.6
-24.5
-12.8
-8.52
-26.8
-46
-90.1
86.7
Income tax
-0.02
-0.04
-0.13
-0.02
-0.03
0.03
-0.03
0
15.4
3.45
Net income
-16.5
-43.4
-56.5
-24.5
-12.8
-8.56
-26.8
-46
-106
83.2
EBITDA
-37.3
-33
-55.6
-20
-5.34
7.99
-41.6
-48.6
-80.6
-58.9
EPS, basic
-18.01
-47.18
-50.21
-13.23
-3.21
-2.11
-0.78
-1.30
-2.28
1.40
EPS, diluted
-18.01
-47.18
-50.21
-13.23
-3.21
-2.11
-0.78
-1.30
-2.28
1.35
Shares, basic (weighted)
0.92
0.92
1.12
1.85
3.98
29.8
34.5
35.5
46.3
55.3
Shares, diluted (weighted)
0.92
0.92
1.12
1.85
3.98
29.8
34.5
35.5
46.3
57.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
16.8
10.9
18.4
3.22
4.21
112
65.5
43
33.8
62.4
Short-term investments
51
31.4
3.26
0
16.9
24.7
35.7
129
Receivables
5
2.01
0
1.68
2.44
1.42
7.19
16.1
10.2
Inventory
0.67
0
1.97
1.74
Other current assets
0.49
1.66
1.91
1.55
1.48
1.18
1.69
1.82
4.05
7
Total current assets
74.4
45.9
23.7
6.97
8.38
115
92.8
86.9
86
223
Property, plant and equipment
1.97
2
1.75
1.47
1.04
0.88
0.79
0.74
0.36
0.49
Lease right-of-use assets
1.54
1.35
1.14
0.99
0.79
0.66
1.21
Goodwill
0
4.7
4.7
4.7
Intangible assets
0
69.2
69
6.42
Long-term investments
8.2
3.25
0
15.4
0
0
6.01
47.9
Other non-current assets
0.36
0.21
0.56
0.53
0.44
0.44
0.05
0.09
0.38
0.14
Total assets
84.9
52.5
26.7
10.5
11.2
133
115
172
178
285
Accounts payable
0.47
2.18
3.72
1.14
1.17
0.52
3.61
14
13.1
2.48
Accrued liabilities
0.7
0.7
0.7
0.7
0.7
0.7
0
Total current liabilities
6.64
11.5
12
5.43
7.54
4.23
12
73.7
34.1
39.3
Long-term debt
0
5.07
59.5
61.9
Lease liabilities
1.9
1.59
1.23
0.84
0.46
0.37
0.86
Other non-current liabilities
0.5
0.79
0.69
0.17
0.15
0.03
0.03
7.46
4.63
1.71
Total liabilities
104
110
93.3
85
77.6
5.82
40.2
110
138
130
Total debt
92.7
81.4
77.3
67.7
5.07
59.5
61.9
Paid-in capital
103
107
155
171
192
397
436
473
555
588
Retained earnings
-121
-165
-221
-246
-258
-267
-354
-400
-505
-422
Treasury stock
0
-2.81
-7.54
-11
-11
-11
Other comprehensive income
0
0.11
-0.04
0.63
-0.76
Shareholders' equity
-18.7
-57.5
-66.6
-74.5
-66.4
102
75.1
61.9
39.7
155
Total equity
-18.7
-57.5
-66.6
-74.5
-66.4
102
75.1
61.9
39.7
155
Total liabilities and equity
84.9
52.5
26.7
10.5
11.2
133
115
172
178
285
Shares outstanding
0.92
0.92
0.1
2.27
4.54
35
34.5
41.5
53.7
56.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-16.5
-43.4
-56.5
-24.5
-12.8
-8.56
-26.8
-46
-106
83.2
Depreciation and amortization
0.18
0.34
0.32
0.3
0.27
0.26
0.94
1.01
6.39
4.05
Stock-based compensation
6.6
4.56
6.5
4.41
2.49
2.44
4.29
5.95
14.9
12.6
Deferred income tax
15.4
-9.85
Change in inventory
0
0.15
0.21
-8.87
-1.31
Change in payables
1.12
-0.8
-1.64
-3.79
0.93
-1.11
3.13
11.1
-3.6
-15.6
Cash from operations
-29.8
-33.1
-54.2
-23.7
-1.94
10.4
-18.7
-33.5
-69.7
-1.6
Capital expenditures
-0.64
-0.18
-0.02
-0.03
-0.03
-0.1
-0.09
-0.3
0
-0.84
Acquisitions
0
-14.1
-30.4
0
Purchases of investments
-89.8
-27.4
0
-15.4
-23.9
-45.8
Sales and maturities of investments
44.6
55
33.4
3.26
1.33
59.1
25
179
Cash from investing
-45.8
27.4
33.3
3.23
-0.03
-15.5
-36.7
-17.4
-22.2
18.1
Debt issued
82.8
0.78
0
12.8
42.4
59
0
Debt repaid
0
-17.5
-42.7
0
Stock issued
4.83
0
6.11
64.5
0
Share buybacks
0
-2.81
-4.72
-3.45
0
Cash from financing
61.2
-0.2
28
4.94
2.74
113
8.35
28.5
82.1
12.1
Net change in cash
-14.5
-5.89
7.15
-15.6
0.77
108
-46.9
-22.4
-9.26
28.6
Free cash flow
-30.4
-33.3
-54.2
-23.8
-1.97
10.3
-18.8
-33.8
-69.7
-2.43
Interest paid
3.29
5.72
5.54
5.36
0.08
0.22
0.32
0.46
5.26
5.33
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $11.04 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
95.5%
Gross profit / revenue.
Operating margin
60.5%
Operating income / revenue.
EBITDA margin
61.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
50.9%
Pre-tax income / revenue.
Net margin
42.8%
Net income / revenue.
FCF margin
24.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
24.5%
Cash from operations / revenue.
Effective tax rate
15.9%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
26.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
19.2%
Net income / average total assets.
Return on invested capital (ROIC)
95.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
11.0%
Research and development expense / revenue.
SG&A / revenue
54.8%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
9.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.6%
Capital expenditures / revenue.
D&A / revenue
1.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
350.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
118.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
51.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
455.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
108.4%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
289.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
27.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
59.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
35.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
91.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
23.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
18.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
70.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.17x
Current assets / current liabilities.
Quick ratio
4.56x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.56x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
28.1%
Total liabilities / total assets.
Net debt
-$221.6M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
-2.64x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Free cash flow / net income, when net income is positive.
Capex / operating cash flow
2.3%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.95
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.22
Revenue / diluted weighted shares.
FCF per share
$0.53
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.54
Cash from operations / diluted weighted shares.
Book value per share
$3.67
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
11.3x
Market cap / net income. Only when net income is positive.
P/S
4.82x
Market cap / revenue.
P/B
3.01x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.16x
Market cap / tangible book value, when positive.
P/FCF
20.1x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
19.6x
Market cap / cash from operations, when positive.
EV/Sales
3.19x
Enterprise value / revenue.
EV/EBIT
5.27x
Enterprise value / operating income, when both are positive.
EV/EBITDA
5.18x
Enterprise value / EBITDA, when both are positive.
EV/FCF
13.3x
Enterprise value / free cash flow, when both are positive.
FCF yield
5.0%
Free cash flow / market cap.
Earnings yield
8.9%
Net income / market cap (the inverse of P/E).
What was ZEVRA THERAPEUTICS, INC.'s revenue in fiscal 2025?
ZEVRA THERAPEUTICS, INC. reported revenue of $106.5M for fiscal 2025, 350.9% higher than the year before.
Was ZEVRA THERAPEUTICS, INC. profitable in fiscal 2025?
Yes. Net income was $83.2M, a net margin of 78.2%.
How much free cash flow did ZEVRA THERAPEUTICS, INC. generate in fiscal 2025?
Cash from operations of $1.6M minus capital expenditures of $835.0K left free cash flow of -$2.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.